Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Cerecor Inc is a biotechnology business based in the US. Cerecor shares (CERC) are listed on the NASDAQ and all prices are listed in US Dollars. Cerecor employs 18 staff and has a trailing 12-month revenue of around USD$6.9 million.
|Latest market close||USD$2.64|
|52-week range||USD$1.52 - USD$6.19|
|50-day moving average||USD$2.4303|
|200-day moving average||USD$2.5527|
|Wall St. target price||USD$11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.894|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||9.09%|
|1 month (2020-11-05)||26.32%|
|3 months (2020-09-04)||18.39%|
|6 months (2020-06-05)||-3.30%|
|1 year (2019-12-05)||-21.66%|
|2 years (2018-12-04)||-22.58%|
|3 years (2017-12-05)||60.00%|
|5 years (2015-12-04)||-25.63%|
|Revenue TTM||USD$6.9 million|
|Gross profit TTM||USD$-4,879,126|
|Return on assets TTM||-25.19%|
|Return on equity TTM||-127.56%|
|Market capitalisation||USD$182.3 million|
TTM: trailing 12 months
There are currently 1.4 million Cerecor shares held short by investors – that's known as Cerecor's "short interest". This figure is 6.4% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting Cerecor shares can be evaluated.
Cerecor's "short interest ratio" (SIR) is the quantity of Cerecor shares currently shorted divided by the average quantity of Cerecor shares traded daily (recently around 422958.02469136). Cerecor's SIR currently stands at 3.24. In other words for every 100,000 Cerecor shares traded daily on the market, roughly 3240 shares are currently held short.
However Cerecor's short interest can also be evaluated against the total number of Cerecor shares, or, against the total number of tradable Cerecor shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cerecor's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cerecor shares in existence, roughly 20 shares are currently held short) or 0.0304% of the tradable shares (for every 100,000 tradable Cerecor shares, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cerecor.
Find out more about how you can short Cerecor stock.
We're not expecting Cerecor to pay a dividend over the next 12 months.
Over the last 12 months, Cerecor's shares have ranged in value from as little as $1.52 up to $6.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cerecor's is 1.679. This would suggest that Cerecor's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.